Heterologous expression of wild-type and Lys99Ala mutant L-asparaginase from Lachancea thermotolerans in Pichia pastoris: culture optimization and laboratory-scale bioreactor production.

L-Asparaginase (L-ASNase) is an enzyme of significant therapeutic value within the pharmaceutical industry, primarily due to its clinical efficacy in treating acute lymphoblastic leukemia (ALL). Despite its benefits, the clinical application of commercially available bacterial-derived L-ASNases is frequently impeded by severe hypersensitivity reactions and immunogenicity. This limitation has necessitated the exploration of novel L-ASNase variants and the development of alternative heterologous expression systems that minimize adverse immune responses. As unicellular eukaryotic models, yeast-based expression platforms represent a robust alternative for the production of therapeutic proteins. In the present study, the asnase gene from Lachancea thermotolerans (L. thermotolerans, LtASNase), along with its Lys99Ala mutant variant was heterologously expressed in Pichia pastoris (P. pastoris). To maximize yield, cultivation parameters were systematically optimized, followed by scale-up in a bioreactor under stabilized conditions. Initial shake-flask cultivations of the wild-type and mutant LtASNase yielded maximum whole-cell activities of 191 U g